

Contents

List of contributing authors — XI

Dinesh Kumar, Pooja Sharma, Ayush Mahajan, Ravi Dhawan, and Kamal Dua

1 Pharmaceutical interest of *in-silico* approaches — 1

- 1.1 Introduction — 1
- 1.1.1 Target recognition — 2
- 1.1.2 Target confirmation — 2
- 1.1.3 Lead discovery — 2
- 1.1.4 Lead optimization — 2
- 1.1.5 Preclinical studies — 2
- 1.1.6 Clinical trials — 3
- 1.2 Approaches — 3
- 1.2.1 Homology modeling (HM) — 3
- 1.2.2 Molecular docking (Interaction Networks) — 3
- 1.2.3 Virtual high-throughput screening — 6
- 1.2.4 Quantitative structure-activity relationship (QSAR) — 7
- 1.2.5 Hologram quantitative structure-activity relationship (HQSAR) — 8
- 1.2.6 Comparative molecular similarity indices analysis (CoMSIA) — 8
- 1.2.7 3D-pharmacophore mapping — 8
- 1.2.8 De novo design based on 3D-pharmacophore mapping — 9
- 1.2.9 Microarray analysis — 9
- 1.2.10 Conformational analysis — 9
- 1.2.11 Monte Carlo simulation — 10
- 1.2.12 Molecular dynamic (MD) simulation — 10
- References — 11

Mohammad Kalim Ahmad Khan and Salman Akhtar

2 Novel drug design and bioinformatics: an introduction — 15

- 2.1 Introduction — 15
- 2.2 Structure-based drug design — 19
- 2.2.1 Homology modelling — 19
- 2.2.2 Ligand docking — 22
- 2.2.3 Fragment-based drug design — 23
- 2.2.4 Molecular dynamics — 25
- 2.3 Ligand-based drug design — 26
- 2.3.1 Similarity search — 27
- 2.3.2 Pharmacophore mapping — 27
- 2.3.3 Quantitative structure-activity relationship — 27
- 2.4 Quantum mechanics/molecular mechanics — 28

2.5	Proteomchemometrics modelling —	28
2.6	Deep learning approach —	29
2.7	Summary and outlook —	29
	References —	30

Shaheen Begum, Mohammad Zubair Shareef and Koganti Bharathi

3	<i>In silico</i> drug design: application and success —	37
3.1	Introduction to <i>in silico</i> drug design —	38
3.1.1	Introduction —	38
3.1.2	Classification —	38
3.1.3	Structure-based drug design (SBDD) —	38
3.1.4	Molecular docking —	40
3.1.5	Pharmacophore generation —	42
3.1.6	Virtual screening (VS) —	44
3.2	SBDD and applications —	45
3.2.1	Introduction —	45
3.2.2	The successful drugs developed using <i>in silico</i> approaches —	45
3.3	Ligand based drug design (LBDD) and applications —	53
3.3.1	Introduction —	53
3.3.2	Molecular descriptors-role in LBDD —	53
3.3.3	<i>In silico</i> applications of QSAR analysis —	54
3.3.4	Extended applications of QSAR combined with SBDD techniques —	56
3.3.5	Applications of mt-QSAR and mtk-QSAR models —	57
3.3.6	Success in the field of LBDD —	58
3.4	<i>In silico</i> approaches-application to predict pharmacokinetic parameters and toxicity (ADMET) —	62
3.4.1	<i>In silico</i> tools to predict absorption —	62
3.4.2	<i>In silico</i> tools to predict the distribution —	65
3.4.3	<i>In silico</i> tools to predict metabolism —	71
3.4.4	<i>In silico</i> tools to predict toxicity —	73
3.5	Conclusion —	79
	References —	79

Rodrigo S. A. de Araújo, Francisco J. B. Mendonça, Jr., Marcus T. Scotti and Luciana Scotti

4	Protein modeling —	85
4.1	Proteins —	85
4.2	Bioinformatics and the importance of computational tools —	87
4.3	Homologous structures and <i>de novo</i> protein design —	88
4.4	Protein data bank —	89
4.5	Molecular modeling —	90
4.5.1	Comparative modeling —	91
4.5.2	Free modeling —	91

4.6	Selected computational tools —	94
4.6.1	PyMOL —	94
4.6.2	Pfam —	95
4.7	SWISS-MODEL —	96
4.8	Critical assessment of protein structure prediction (CASP) —	97
4.9	Conclusion —	97
	References —	98

Rahul Ashok Sachdeo, Tulika Anthwal and Sumitra Nain

5	Fragment based drug design —	101
5.1	Introduction —	101
5.1.1	Fragment —	104
5.1.2	Design of library —	106
5.1.3	Identification of appropriate fragment to develop (biophysical or biochemical techniques, which interrogate the ligand–target binding) [1, 14, 15] —	106
5.1.4	Elaborating its chemical structure to generate a useful lead compound —	110
5.1.5	Growing —	110
5.1.6	Merging —	111
5.1.7	Linking —	111
5.2	Conclusion —	112
	References —	113

Richie R. Bhandare, Bulti Bakchi, Dilep Kumar Sigalapalli and Afzal B. Shaik

6	An overview of <i>in silico</i> methods used in the design of VEGFR-2 inhibitors as anticancer agents —	115
6.1	Introduction —	115
6.2	History of earlier FDA-approved VEGFR kinase inhibitors and the recent development —	117
6.3	Structure of VEGFR-2 —	118
6.4	Applications of <i>in silico</i> studies in the exploration of VEGFR-2 inhibitors —	119
6.4.1	Design of novel piperazine–chalcone hybrids as VEGFR-2 kinase inhibitors —	120
6.4.2	Docking model of 1-piperazinyl-phthalazines as potential VEGFR-2 inhibitors —	121
6.4.3	Identification of BAW2881 as a potent VEGFR-2 inhibitor: a success story —	122
6.4.4	Molecular modeling studies on thienopyrimidine scaffold as VEGFR-2 inhibitors —	124

- 6.4.5 Identification of new VEGFR-2 kinase inhibitors: pharmacophore modeling and virtual screening — **125**
- 6.4.6 Molecular modeling of quinazoline containing 1,3,4-oxadiazole scaffold as VEGFR-2 inhibitor — **125**
- 6.4.7 Identification of covalently binding, irreversible VEGFR-2 kinase domain inhibitors — **126**
- 6.4.8 Molecular docking study of novel *N*-(2-carbamoyl-6-methoxyphenyl)-3,4,5-trimethoxybenzamide derivative as VEGFR-2 tyrosine kinase inhibitor — **128**
- 6.5 Conclusions — **128**
- References — **129**

Varruchi Sharma, Anil Panwar, Girish Kumar Gupta and Anil K. Sharma

7 Molecular docking and MD: mimicking the real biological process — 133

- 7.1 Introduction — **133**
- 7.2 AutoDock; docking of flexible ligands to receptors: — **134**
- 7.3 AutoDock: coordinate file preparation — **135**
- 7.4 Autogrid calculation — **135**
- 7.5 Docking performed using AutoDock — **136**
- 7.6 Analysis performed using AutoDock tools — **136**
- 7.7 AutoDock result — **136**
- 7.8 Molecular dynamic simulations and history — **138**
- 7.9 PDB Structure and need of 3d conformation study — **138**
- 7.10 Conformational changes are a common part of an enzymes' catalytic cycle — **138**
- 7.11 The overview of calculating md simulation — **139**
- 7.12 GPU and high computation power in MD simulations — **139**
- 7.13 World's fastest computer and MD simulations — **141**
- 7.14 Force filed: need and selection — **142**
- 7.15 Benefits/outcomes of MD simulations — **142**
- 7.16 Limitations and future prospects of MD simulations — **142**
- References — **143**

Babar Ali, Qazi Mohammad Sajid Jamal, Showkat R. Mir, Saiba Shams, and Mohammad Amjad Kamal

8 Molecular docking studies of tea (*Thea sinensis* Linn.) polyphenols inhibition pattern with Rat P-glycoprotein — 145

- 8.1 Introduction — **145**
- 8.2 Materials and methods — **147**
- 8.2.1 3D modeling of Rat P-gp receptor — **147**
- 8.2.2 Template search — **147**
- 8.2.3 Template selection — **147**

8.2.4	Model building —	148
8.2.5	Model quality estimation —	148
8.2.6	Model validation —	148
8.2.7	Preparation of receptor molecule —	148
8.2.8	Ligand optimization —	149
8.2.9	Docking studies —	149
8.3	Results —	149
8.4	Discussion —	154
8.5	Conclusion —	154
	Abbreviations —	154
	References —	155

Nermin A. Osman

9	Statistical methods for <i>in silico</i> tools used for risk assessment and toxicology —	157
9.1	Background —	157
9.2	Risk assessment comprises four processes —	159
9.2.1	Hazard identification —	159
9.2.2	Exposure assessment —	159
9.2.3	Effect assessment —	159
9.2.4	Risk characterization —	160
9.3	Risk management —	160
9.3.1	<i>In silico</i> tools used for risk assessment —	160
9.3.2	Statistical methods for <i>in silico</i> risk assessment —	164
	References —	168

Maya Madhavan and Sabeena Mustafa

10	Systems biology—the transformative approach to integrate sciences across disciplines —	171
10.1	Introduction —	171
10.2	Transforming biology-insights from the systems biology approach —	173
10.2.1	Systems and systems biology —	173
10.2.2	Network modelling in systems biology —	177
10.2.3	From systems biology to synthetic biology —	177
10.2.4	Applications of synthetic biology —	179
10.3	Challenges and future directions —	188
10.4	Conclusions —	189
	References —	189